User profiles for Sharon L. Achilles
Sharon AchillesUniversity of Pittsburgh Verified email at upmc.edu Cited by 1768 |
[HTML][HTML] Impact of contraceptive initiation on vaginal microbiota
SL Achilles, MN Austin, LA Meyn, F Mhlanga… - American journal of …, 2018 - Elsevier
Background Data evaluating the impact of contraceptives on the vaginal microbiome are
limited and inconsistent. Objective We hypothesized that women initiating copper intrauterine …
limited and inconsistent. Objective We hypothesized that women initiating copper intrauterine …
The evolving facets of bacterial vaginosis: implications for HIV transmission
Bacterial vaginosis (BV) is a common yet poorly understood vaginal condition that has become
a major focus of HIV transmission and immunology research. Varied terminologies are …
a major focus of HIV transmission and immunology research. Varied terminologies are …
Prevention of infection after induced abortion
SL Achilles, MF Reeves - Contraception, 2011 - Elsevier
One known complication of induced abortion is upper genital tract infection, which is relatively
uncommon in the current era of safe, legal abortion. Currently, rates of upper genital tract …
uncommon in the current era of safe, legal abortion. Currently, rates of upper genital tract …
The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota
SL Achilles, SL Hillier - Aids, 2013 - journals.lww.com
The same populations of women at risk for sexual acquisition of HIVare also at risk for
pregnancy; many of these women use contraception. Combating the spread of HIV is a major …
pregnancy; many of these women use contraception. Combating the spread of HIV is a major …
[HTML][HTML] Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results
…, MJ Chen, JT Jensen, AM Kaunitz, SL Achilles… - Contraception, 2021 - Elsevier
Objective To assess efficacy, cycle control, and safety of an oral contraceptive containing
estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. Study design Women aged 16 to 50 years …
estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. Study design Women aged 16 to 50 years …
Changes in genital tract immune cell populations after initiation of intrauterine contraception
Objective The primary target cells for the human immunodeficiency virus (HIV) infection in the
genital tract are CD4 T cells that express CCR5 on the surface. Alterations in genital tract T …
genital tract are CD4 T cells that express CCR5 on the surface. Alterations in genital tract T …
Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention
SA Krovi, LM Johnson, E Luecke, SL Achilles… - Advanced drug delivery …, 2021 - Elsevier
Worldwide, women face compounding reproductive health risks, including human
immunodeficiency virus (HIV), sexually-transmitted infections (STIs), and unintended pregnancy. …
immunodeficiency virus (HIV), sexually-transmitted infections (STIs), and unintended pregnancy. …
[HTML][HTML] Misreporting of contraceptive hormone use in clinical research participants
SL Achilles, FG Mhlanga, P Musara, SM Poloyac… - Contraception, 2018 - Elsevier
Objective Researchers traditionally rely on participant self-report for contraceptive use. We
hypothesized that self-reported contraceptive use by clinical research participants may …
hypothesized that self-reported contraceptive use by clinical research participants may …
Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy
…, SA Riddler, SE Cohn, KM Darin, SL Achilles… - AIDS, 2017 - journals.lww.com
Objectives: The primary objective of this study was to characterize the pharmacokinetics of
etonogestrel (ENG) released from a contraceptive implant in Ugandan women living with HIV …
etonogestrel (ENG) released from a contraceptive implant in Ugandan women living with HIV …
[HTML][HTML] Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials
… /L at baseline, had a value of 8.0 mmol/L 18 days after last study drug use. The other 5
participants had potassium values of 5.5 to 6.0 mmol/L, one of whom (6.0 mmol/L) discontinued. …
participants had potassium values of 5.5 to 6.0 mmol/L, one of whom (6.0 mmol/L) discontinued. …